Key Takeaways
- • Gilead Sciences is acquiring Munich-based biotech Tubulis for $3.15 billion upfront, plus up to $1.85 billion in milestone payments, representing the company's third major M&A deal in 2026 as it expands its oncology pipeline.
- • Tubulis brings two clinical-stage antibody-drug conjugate (ADC) programs: TUB-040 (targeting NaPi2b for ovarian and lung cancers, showing a 50% overall response rate in Phase 1b/2 trials) and TUB-030 (targeting 5T4 across 13 solid tumor types in a basket study).
- • The acquisition's strategic value extends beyond the two clinical candidates to Tubulis's next-generation ADC platform technologies, which feature highly stable linkers and enable higher drug-antibody ratios and novel payload types (cytotoxins, protein degraders, immune modulators) applicable to oncology, immunology, and virology.
- • Gilead's prior 2024 partnership with Tubulis—a $20 million upfront collaboration—provided conviction in Tubulis's capabilities and will advance an undisclosed ADC program to preclinical development, demonstrating platform validation.
- • Analysts highlight the platform's cross-therapeutic potential, particularly for antiviral applications in HIV and influenza drug development, positioning this deal similarly to Merck's $9.2 billion Cidara acquisition, which leverages platform technology across multiple disease areas.
Summary
Gilead Sciences is acquiring Tubulis, a German antibody-drug conjugate specialist, for $3.15 billion in upfront cash with up to $1.85 billion in additional milestone payments. The transaction, announced April 8, 2026, marks Gilead's third major acquisition this year, following the February $7.8 billion purchase of cell therapy company Arcellx and the March $1.7 billion acquisition of Ouro Medicines. The deal underscores Gilead's strategic pivot beyond its historical virology strength to prioritize immunology and oncology, with a particular focus on acquiring platform technologies that extend across therapeutic areas.
Tubulis contributes two clinical-stage ADC candidates to Gilead's pipeline. TUB-040, the lead program, targets NaPi2b and is in Phase 1b/2 testing for platinum-resistant ovarian cancer and non-small cell lung cancer. First interim data presented at the European Society for Medical Oncology meeting in fall 2025 demonstrated a 50% overall response rate across 66 evaluable ovarian cancer patients, with the majority of treatment-related adverse events classified as Grade 1 or 2. TUB-030, the second candidate, targets 5T4 and is being evaluated in a basket study spanning 13 solid tumor types. Prior to the acquisition, Tubulis raised €344 million (approximately $401 million) in a Series C financing round, which gained momentum after the ESMO presentation.
The deal's strategic foundation rests on Tubulis's platform technologies rather than the clinical candidates alone. Tubulis specializes in developing ADCs with improved stability—a critical advantage over existing therapies, which sometimes release drug payloads prematurely, causing off-target toxicity. Gilead Chief Medical Officer Dietmar Berger highlighted two proprietary platforms: one producing highly stable linkers that enable high drug-antibody ratios (DAR) for more potent delivery while maintaining circulation stability, and another enabling novel payload types including cytotoxins, protein degraders, and immune modulators. These capabilities address a fundamental challenge in ADC development; competitors including Zymeworks and Mersana Therapeutics have previously abandoned NaPi2b-targeting efforts, underscoring the technical difficulty of the target.
Gilead's confidence in Tubulis's technology derives from a 2024 partnership in which the company paid $20 million upfront to collaborate on an undisclosed ADC target, granting exclusive licensing rights. That collaboration has advanced to preclinical development and demonstrated Tubulis's technological capabilities to Gilead. CEO Daniel O'Day stated the acquisition would "further expand what is already the strongest and most diverse pipeline in our company's history." Leerink Partners analyst Daina Graybosch noted the platform's cross-therapeutic potential, drawing parallels to Merck's $9.2 billion Cidara acquisition, which leveraged platform technology beyond its primary indication. Gilead's interest extends to antiviral applications, particularly for HIV and other infectious diseases, positioning Tubulis's ADC platform as a multimodal asset applicable to oncology, immunology, and virology through novel payload development.
Tubulis contributes two clinical-stage ADC candidates to Gilead's pipeline. TUB-040, the lead program, targets NaPi2b and is in Phase 1b/2 testing for platinum-resistant ovarian cancer and non-small cell lung cancer. First interim data presented at the European Society for Medical Oncology meeting in fall 2025 demonstrated a 50% overall response rate across 66 evaluable ovarian cancer patients, with the majority of treatment-related adverse events classified as Grade 1 or 2. TUB-030, the second candidate, targets 5T4 and is being evaluated in a basket study spanning 13 solid tumor types. Prior to the acquisition, Tubulis raised €344 million (approximately $401 million) in a Series C financing round, which gained momentum after the ESMO presentation.
The deal's strategic foundation rests on Tubulis's platform technologies rather than the clinical candidates alone. Tubulis specializes in developing ADCs with improved stability—a critical advantage over existing therapies, which sometimes release drug payloads prematurely, causing off-target toxicity. Gilead Chief Medical Officer Dietmar Berger highlighted two proprietary platforms: one producing highly stable linkers that enable high drug-antibody ratios (DAR) for more potent delivery while maintaining circulation stability, and another enabling novel payload types including cytotoxins, protein degraders, and immune modulators. These capabilities address a fundamental challenge in ADC development; competitors including Zymeworks and Mersana Therapeutics have previously abandoned NaPi2b-targeting efforts, underscoring the technical difficulty of the target.
Gilead's confidence in Tubulis's technology derives from a 2024 partnership in which the company paid $20 million upfront to collaborate on an undisclosed ADC target, granting exclusive licensing rights. That collaboration has advanced to preclinical development and demonstrated Tubulis's technological capabilities to Gilead. CEO Daniel O'Day stated the acquisition would "further expand what is already the strongest and most diverse pipeline in our company's history." Leerink Partners analyst Daina Graybosch noted the platform's cross-therapeutic potential, drawing parallels to Merck's $9.2 billion Cidara acquisition, which leveraged platform technology beyond its primary indication. Gilead's interest extends to antiviral applications, particularly for HIV and other infectious diseases, positioning Tubulis's ADC platform as a multimodal asset applicable to oncology, immunology, and virology through novel payload development.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.